A review of cyclotrons for Hadron Therapy. Y. Jongen Cyclotrons 2010 Lanzhou, September

Similar documents
REVIEW ON CYCLOTRONS FOR CANCER THERAPY

Introduction to Ion Beam Cancer Therapy

An Introduction to Cancer Therapy With Hadron Radiation

PROGRESS IN HADRONTHERAPY

Status of Hadrontherapy facilities worldwide

Future dosimetry issues: protons, hadrons & MR linacs

Aspects of Industrialization of Accelerators for Particle Therapy ICABU, November 11, 2013, Daejeon

Review of Hadron machines for cancer therapy

Review of Heavy Ion Accelerators for Hadrontherapy

United States Proton Therapy Market (Actual & Potential), Patients Treated, List of Proton Therapy Centers and Forecast to 2022

SUMITOMO Particle Therapy Technologies

Heavy Ion Tumor Therapy

SCIENTIFIC AND TECHNOLOGICAL DEVELOPMENT OF HADRONTHERAPY

Workshop on Hadron Beam Therapy of Cancer Erice, Sicily April 24-May

Particle Therapy- Why?

H. Röcken, M. Abdel-Bary, E. Akcöltekin, P. Budz, T. Stephani, J. Wittschen

Present Status and Future Developments in Proton Therapy

Proton Therapy Market Outlook - Global Analysis

III. Proton-therapytherapy. Rome SB - 5/5 1

Road Map for the development of hadron therapy and associated nuclear medicine methods at JINR:

Press release Regulated information

Proton Therapy Dosimetry & Clinical Implementation. Baldev Patyal, Ph.D., Chief Medical Physicist Department of Radiation Medicine

Progress of Heavy Ion Therapy

The Advantages of Particle Therapy and the Status of the Heidelberg Iontherapy Center

The Heidelberg Ion Therapy Center. Thomas Haberer Heidelberg Ion Therapy Center Hadron Therapy Workshop, Erice 2009

Heidelberg Ion-Beam Therapy Centre (HIT) officially opened

Status of Proton Therapy: results and future trends

Chapter 41 New Facilities: Plans and Proposals

ACCELERATORS FOR HADRONTHERAPY

CYCLOTRON PERFORMANCE AND NEW DEVELOPMENTS

Basic Press Information

Nuclear Physics in Proton Radiotherapy

PARTICLES. The deadline for the next newsletter is November , so that Particles 9 can come out in January Address all correspondence to:

NUCLEAR PHYSICS FOR MEDICINE - HADRON THERAPY. Pawel Olko Institute of Nuclear Physics Krakow Poland

Jefferies Healthcare Conference

Cancer Treatment by Charged Particles - Carbon Ion Radiotherapy -

PAMELA Particle Accelerator for MEdicaL Applications

Nuclear Instruments and Methods in Physics Research A

Look! Borg get upgrade already!

Ion Beam Therapy should we prioritise research on helium beams?

The Heidelberg Ion Therapy Center and PARTNER. Thomas Haberer Heidelberg Ion Therapy Center

Maintenance and Logistics Experience at Loma Linda Proton Treatment Facility

TERA PROGRAMME: MEDICAL APPLICATIONS OF PROTONS AND IONS

New Treatment Research Facility Project at HIMAC

Particle Therapy in the 21st Century: Relevance to Developing Countries

along their path through the body damaging healthy cells as they go clinicians and

Activities at the Heidelberg Ion Therapy Center (HIT)

Protonterapia e applicazione clinica

CERN: from particle physics to medical applications. Manuela Cirilli CERN Knowledge Transfer Life Sciences Section

HEAVY PARTICLE THERAPY

ABSTRACTS. of the NIRS International Seminar on the Heavy Charged Particle Therapy for Cancer and the XXVII PTCOG MEETING.

Summary of Synchrotron for Hadron Therapy

Status of H 1 and C 12

Early X-Ray Therapy Machines. Colin G. Orton, Ph.D. Professor Emeritus, Wayne State University, Detroit, Michigan, USA

Planning for the Installation of a Compact Superconducting Proton Therapy Unit in a Busy Medical Center Environment

S m u m m a m ry y Ta T lk of o the h Wo W r o ksho h p Accelerators for IBT Linz-MediConsult U e e L i L nz n Forschungszentrum Jülich

Learning Objectives. Clinically operating proton therapy facilities. Overview of Quality Assurance in Proton Therapy. Omar Zeidan

PARTICLES. A Newsletter. for those interested in proton, light ion and heavy charged particle radiotherapy. T C P ROTON HERAPY O- PERATIVE ROUP

REVIEW OF NEUTRON AND PROTON THERAPY

Present status and future of Proton beam therapy

OPERATION AND PATIENT TREATMENTS AT CNAO FACILITY

Particle Therapy Systems by Mitsubishi Electric DG1101-KM-0034

Applications of Particle Accelerators

The first year of operation of PSI s new SC cyclotron and beam lines for proton therapy.

The national center for oncological hadron therapy: status of the project and future clinical use of the facility

Tumor Therapy with Heavy Ions at GSI Darmstadt

By Elizabeth Clements. Applications in cancer treatment

PARTICLES. Other proton therapy links: (this list is probably not complete, so PLEASE send me your URL to include in the next issue)

Characterization and implementation of Pencil Beam Scanning proton therapy techniques: from spot scanning to continuous scanning

Cancer: A Medical Challenge for Physics

PARTICLES P ARTICLE T HERAPY G ROUP. A Newsletter for those interested in proton, light ion and heavy charged particle radiotherapy.

HEALTH RISKS FROM EXPOSURE TO FAST NEUTRONS. Prof. Marco Durante

Cell Survival vs Irradiation dose

Practical Challenges and Opportunities for Proton Beam Therapy. M. F. Moyers Loma Linda University Medical Center

HADRONTHERAPY IN THE WORLD

The Best in Proton Therapy + Today and Tomorrow + IBA. Corporate Presentation. February 2017

The Heidelberg Ion Therapy (HIT) Accelerator Coming Into Operation. Presented at EPAC 2008, Genova D. Ondreka, GSI

Proceedings of the 7th International Conference on Cyclotrons and their Applications, Zürich, Switzerland

Proton Treatment. Keith Brown, Ph.D., CHP. Associate Director, Radiation Safety University of Pennsylvania

Large-area Two-Dimensional Thermoluminescence Dosimetry System in Ion Beam Quality Assurance

HIMAC AND MEDICAL ACCELERATOR PROJECTS IN JAPAN

Accelerator Seminar, April 2013

HADRONTHERAPY: a new frontier for cancer treatment

IN VIVO IMAGING Proton Beam Range Verification With PET/CT

Prof. Dr. Thomas Haberer Scientific-technical Director Heidelberg Iontherapy Center

The Royal College of Radiologists RCR-Cyclotron Trust Visiting Fellowships 2017 (Clinical Oncology) POST-VISIT REPORT

Firing Protons at Lesions

PARTICLES. A Newsletter. for those interested in proton, light ion and heavy charged particle radiotherapy. T C P ROTON HERAPY O- PERATIVE ROUP

MEDICAL PHYSICS ASPECTS OF PARTICLE THERAPY Oliver Jäkel 1,2, *

Plans for the Precision Cancer Medicine Institute University of Oxford

ACI s 2nd Annual PLANNING, BUILDING AND OPERATING SUCCESSFUL. PROTON THERAPY CENTERS Bringing the Leading Edge of Cancer treatment to More Patients

Proton and heavy ion radiotherapy: Effect of LET

Summary Talk of the Workshop

SLAC, the ILC, and the SMTF

COMPARISON OF RADIOBIOLOGICAL EFFECTS OF CARBON IONS TO PROTONS ON A RESISTANT HUMAN MELANOMA CELL LINE

PARTICLES. The deadline for the next newsletter is June , so that Particles 10 can come out in July Address all correspondence to:

COMPACT IMAGE-GUIDED IMPT SOLUTION PROTON THERAPY MADE EASY.

The ANDANTE project: a multidisciplinary approach to neutron RBE

PARTICLES. or

PARTICLES. for those interested in proton, light ion and heavy charged particle radiotherapy. A Newsletter T C P ROTON HERAPY O- PERATIVE ROUP

Transcription:

A review of cyclotrons for Hadron Therapy Y. Jongen Cyclotrons 2010 Lanzhou, September 10 2010

The early days The possible use of the Bragg peak of high energy ions in the radiotherapy of cancer was suggested by Bob Wilson in 1946 But it took two decades to see real clinical use of particle beam therapy in cancer treatment The first patient treatments took place in the late 1950 s and early 1960 s at LBNL in Berkeley, at Uppsala University in Sweden and at Harvard Cyclotron Laboratory (HCL) HCL had a specially important role in developing present day proton therapy techniques, while Berkeley developed the early steps of heavier ions therapy

The Harvard Synchrocyclotron

Andy Koehler and Jason Burns in the MCR (1989)

Early proton treatments by Dr. Kjellberg

Hospital based facilities The successful experience of HCL indicated clearly that it would be better to have the proton therapy facility within the hospital, rather than in an ex-physics laboratory In 1983, the different laboratories developing PT got together and formed the Proton Therapy Cooperative Group (PTCoG) to develop hospital based PT facilities The first achievement of PTCoG was to develop a common set of specifications for an hospital based PT facility These specifications remain today the bible of proton therapy facility developers (even if the validity of some specifications are discussed today)

Loma Linda While most of the early development of proton therapy was made in Harvard, the group led by Pr. James (Jim) Slater at Loma Linda University Medical Center (LLUMC) was the first to be able to raise the funds needed to build a hospital based PT facility The development of the accelerator was subcontracted by LLUMC to a group of experienced accelerator physicists at Fermilab. The accelerator technology selected was a synchrotron and for a long time the synchrotron would be considered the technology of choice for PT The development of the gantries was subcontracted to SAIC A company (named Optivus today) was created by Jim Slater to do the maintenance and development of the LLUMC PT facility Optivus is proposing for sale a PT system closely derived from LLUMC one (but so far have not concluded a contract)

Massachusetts General Hospital (MGH) (1) MGH, who was leading the PT development at HCL got in 1992 from NCI and private donors the budget needed to build an in hospital PT facility. An international tender was launched After a first selection, 3 groups remained in the race: Varian, allied with Maxwell-Brobeck was proposed a synchrotron based system Siemens proposed 2 solutions. One based on a synchrotron, the other based on a superconducting isochronous (designed by Pierre Mandrillon from CERN & Nice) IBA, allied with General Atomics proposed a solution based on a resistive isochronous cyclotron of 230 MeV Eventually, the IBA system was selected by MGH, and the contract was signed in 1994 with the goal to treat a first patient in 1998

Massachusetts General Hospital (MGH) (2) At the end of the MGH tender, one observer noted: «This tender may well cause the end of 3 good accelerator companies: perhaps for the companies which did not get the contract, but certainly for the company that got it». He was very close to be entirely right After the contract with IBA, the Brobeck division of Maxwell was closed The special projects division of Siemens was closed too, and sold to its management. It restarted business under the name of ACCEL, and eventually came back to PT IBA encountered problems too. The cyclotron, beam lines and gantries came on specifications, on time and on budget. But we underestimated badly the effort and methodology needed for the software development. Finally the first patient was treated in 2001, 7 years after the contract (7 years seems to be an invariant for PT systems). The cost overrun was huge! Fortunately, IBA had other profitable activities to avoid bankruptcy

IBA 230 MeV resistive isochronous cyclotron

Inside the cyclotron

Central region

Electrostatic deflector

Energy selection system

Isocentric gantry treatment room

The sales of the IBA system 9 Treating Patients MGH (Boston) MPRI* (Bloomington, In) Wanjie PTC (Zibo, China) UFPTI (Jacksonville, Fl) KNCC (Ilsan, Korea) Procure 1 (Oklahoma City) U-Penn (Philadelphia, Pa) CPO (Orsay, France) Hampton University (Va) 2 in Installation WPE (Essen, Germany) Procure 2 (Warrenville, Il) 5 in Construction Procure 3 (Somerset, Il) ATreP (Trento, Italy) Procure 4 (Seattle, Wa) PTC Prag (Prag, Czech R.) PTC Krakow (Krakow, Poland) *MPRI: Gantry only

1995-2000: Japan leads the way After the MGH order, from 1995 to 2000, the construction of proton therapy facilities concentrated in Japan, where the public authorities financed the construction of 4 PT facilities and one carbon/proton facility. These facilities were built by 3 Japanese companies: Hitachi, Mitsubishi Electric Co (MELCO), and Sumitomo Heavy Industries (SHI) In 1991, IBA and SHI had signed a 10 years collaboration agreement to develop jointly a proton therapy system. The first system installed by SHI at NCC in Kashiwa was built in collaboration (the cyclotron magnet came from IBA). Knowing about the difficulties encountered by IBA at MGH with the software, SHI proposed a much simpler control system for Kashiwa. As a result, in 1998, NCC was the first PT system based on an isochronous cyclotron to treat a patient. After 2000, the orders of PT facilities to industry grew rapidly

Number of systems contracted to industry

PT market share (in treatment rooms): 75% cyclos

After NCC, SHI sold one system to Taiwan

ACCEL-Varian Around 1995, ACCEL decided to return to the field of proton therapy, and asked Henry Blosser to design for them a high extraction efficiency, 250 MeV SC isochronous cyclotron The prototype of the new ACCEL cyclotron was sold to PSI for their new PT facility Then in 2002, ACCEL was selected to deliver a 5 treatment rooms PT facility to the clinic of Dr. Rinecker in Munich Like for IBA, the development and installation of the cyclotron, beam lines and isocentric gantries was more or less on schedule, but major difficulties were encountered for the development of the treatment software Eventually, in 2007, ACCEL was acquired by Varian, the leader in classical (photons) radiotherapy equipment The first patient was treated at the Rinecker PTC in 2009 However, at this date (September 2010) the validation of the Rinecker facility is still ongoing and no new PT orders have been officially confirmed by Varian

ACCEL-Varian superconducting cyclotron

ACCEL-Varian PT facility in Munich

The compact PT system of Still River Systems Around 2004, the Still River Systems company was formed by medical physicists who had shared the PT experience of HCL and MGH: Ken Gall, Miles Wagner and Skip Rosenthal. Their goal was to design and build a one room, very compact PT system based on a very high field (9T) synchrocyclotron mounted on a gantry and rotating around the patient The original design of the cyclotron was made for them by Tim Antaya from MIT, but the further development of the cyclotron was made by SRS, independently from MIT As usually in PT, the new PT system was offered for sale despite the lack of a working prototype, and a number of soft commitment were obtained from prospective customers The development of the prototype was strongly delayed, and to a large extent by problems to reach stable operation of the cyclotron SC magnet

SRS cyclotron Nb-Sn magnet design

SRS cyclotron prototype

SRS PT treatment room

The SRS team after the first extracted beam!

Carbon therapy Like in PT, the initial research in heavier ion therapy took place in national research centers: first LBNL (Bevalac), then NIRS (Himac) then GSI. Realizing the limits of treating patients in a physics laboratory, GSI developed the design of a more compact, hospital based carbon therapy system. The prototype was built at the DKFZ in Heidelberg For carbon acceleration up to 400 MeV/u, a system made of an ECR ion source, a RFQ, a DTL and a synchrotron seemed obvious and was selected in all projects so far. A similar system was developed in a European collaboration led by CERN (the PIMMS design). The prototype of the PIMMS design was adapted and is being constructed in Pavia (CNAO, Italy) Similarly, NIRS developed the design of a compact, hospital based carbon ion facility. The prototype is installed at Gunma university and started treating patients this year. The Gunma NIRS system is available for sale from all big Japanese manufacturers

HIT: Heidelberg Ion Therapy Facility

Cyclotrons in Carbon therapy??? Today, the synchrotron is the natural choice of accelerator in carbon therapy. The rigidity of carbon ions at 400 MeV/u is 6.4 Tm, and synchrotrons have naturally a variable energy. But the same thing was said in proton therapy until 1992, when IBA introduced an effective cyclotron design for PT. Today, 75% of PT facilities are based on cyclotrons Can we bring the same revolution in carbon therapy? Yes we can! IBA has developed, together with a team of the JINR in Dubna the design of an isochronous cyclotron able to accelerate Q/M = ½ ions to 400 MeV/u (see the presentation of N. Morozov in this session) Why selecting the cyclotron? The cyclotron is smaller and cheaper All parameters are constant You operate one accelerator, not 3 accelerators in series The beam is continuous, and can be modulated rapidly in intensity

The IBA C400

Conclusions (1) The initial development of proton and carbon beam therapy took place in national research laboratories But since the MGH tender in 1992-1994, more than 40 proton and carbon therapy facilities were ordered to industry. Roughly half of these 40 systems have been installed and are treating patients These systems built by industry have treated today more than 15,000 patients Initially, following the development of the Loma Linda synchrotron by Fermilab scientists, synchrotron was considered the preferred accelerator technology for proton therapy

Conclusions (2) In 1991, IBA was the first to come with an efficient proton therapy design based on an isochronous cyclotron. Almost 20 years later, 75% of the systems installed or in construction in the world are based on cyclotrons Today, the synchrotron is the preferred accelerator technology for carbon beam therapy But IBA is presenting today a carbon therapy system based on a SC 400 MeV/u isochronous cyclotron We could see tomorrow cyclotrons becoming also the preferred choice for carbon beam therapy

Thank you